Abstract / Summary
PARP inhibitors have transformed treatment of BRCA1/2 -mutated breast cancer but remain limited by acquired resistance, restricted activity in homologous recombination–proficient tumors, and PARP2-related toxicity. This review examines two advances redefining the class: next-generation PARP1-selective inhibitors with improved therapeutic indices, and rational combinations with DNA-repair, epigenetic, immune, endocrine, and antibody-drug conjugate partners. Together, these strategies mark a shift from monotherapy toward mechanism-based combinations that broaden benefit across breast cancer subtypes.
Topics
PARP inhibition in cancer therapyOpen access
Primary Source
npj Breast Cancer